We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation
Read MoreHide Full Article
RedHill Biopharma Ltd. (RDHL - Free Report) announced that the FDA has granted Fast Track designation to its product candidate, RHB-204, for the treatment of nontuberculous mycobacteria (NTM) disease. Pulmonary NTM disease is a chronic and debilitating lung disease.
Please note that the company is currently evaluating the candidate in a phase III study as a first-line, oral monotherapy for pulmonary NTM disease
Notably, the FDA provides a Fast Track designation to help the development and faster review of drugs, which treat serious and unmet medical conditions. The candidate also enjoys Qualified Infectious Disease Product (QIDP) designation and Orphan Drug designation in the United States.
The QIDP designation makes the company’s potential new drug application for the candidate eligible for priority review and accelerated approval. Moreover, the Orphan Drug designation extends the U.S. market exclusivity for RHB-204 for a potential total of 12 years upon FDA approval.
Shares of Redhill have increased 35.6% in the past year against the industry’s 3.8% decline.
The late-stage study evaluating RHB-204 will enroll 125 patients, randomized at a 3:2 ratio to receive either RHB-204 or placebo. The study is planned to evaluate the safety and efficacy of RHB-204, evaluating patient-reported outcomes and sputum culture conversion (SCC) by month 6 of treatment with the candidate compared to placebo. Patients will continue to receive treatment for 12 months from SCC.
Apart from RHB-204, RedHill is also evaluating another oral drug candidate, opaganib as potential treatment for patients hospitalized with COVID-19 pneumonia, advanced cholangiocarcinoma and prostate cancer in separate clinical studies.
Earlier this month, the company announced encouraging preliminary top-line data from an exploratory phase II study evaluating it for COVID-19 pneumonia. Following 14 days of treatment with opaganib, 52.6% of patients no longer required oxygen support versus 22.2% for placebo while 89.5% of patients achieved 50% reduction in supplemental oxygen compared to 66.7% for placebo. Moreover, 73.7% of patients were discharged by day 14 in the opaganib-arm compared to 55.6% for placebo. Median total oxygen requirement over 14 days was reduced by 68% in the opaganib-arm versus 46.7% for placebo.
Meanwhile, RedHill is set to start a phase II/III study on its second coronavirus candidate, RHB-107 for addressing patients with symptomatic COVID-19 who do not require hospitalization. The FDA cleared an investigational new drug application for the study in November.
BioLineRx’s loss per share estimates have narrowed from $1.36 to 84 cents for 2021 over the past 30 days. Shares of the company have increased 41.4% in the past six months.
United Therapeutics’ earnings per share estimates have increased from $11.49 to $11.59 for 2021 over the past 30 days. Over the trailing six months period, shares of the company have rallied 38.6%.
Sierra Oncology’s loss per share estimates have narrowed from $5.89 to $5.65 for 2021 over the past 60 days. In the past six months, shares of the company have gained 36.6%.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation
RedHill Biopharma Ltd. (RDHL - Free Report) announced that the FDA has granted Fast Track designation to its product candidate, RHB-204, for the treatment of nontuberculous mycobacteria (NTM) disease. Pulmonary NTM disease is a chronic and debilitating lung disease.
Please note that the company is currently evaluating the candidate in a phase III study as a first-line, oral monotherapy for pulmonary NTM disease
Notably, the FDA provides a Fast Track designation to help the development and faster review of drugs, which treat serious and unmet medical conditions. The candidate also enjoys Qualified Infectious Disease Product (QIDP) designation and Orphan Drug designation in the United States.
The QIDP designation makes the company’s potential new drug application for the candidate eligible for priority review and accelerated approval. Moreover, the Orphan Drug designation extends the U.S. market exclusivity for RHB-204 for a potential total of 12 years upon FDA approval.
Shares of Redhill have increased 35.6% in the past year against the industry’s 3.8% decline.
The late-stage study evaluating RHB-204 will enroll 125 patients, randomized at a 3:2 ratio to receive either RHB-204 or placebo. The study is planned to evaluate the safety and efficacy of RHB-204, evaluating patient-reported outcomes and sputum culture conversion (SCC) by month 6 of treatment with the candidate compared to placebo. Patients will continue to receive treatment for 12 months from SCC.
Apart from RHB-204, RedHill is also evaluating another oral drug candidate, opaganib as potential treatment for patients hospitalized with COVID-19 pneumonia, advanced cholangiocarcinoma and prostate cancer in separate clinical studies.
Earlier this month, the company announced encouraging preliminary top-line data from an exploratory phase II study evaluating it for COVID-19 pneumonia. Following 14 days of treatment with opaganib, 52.6% of patients no longer required oxygen support versus 22.2% for placebo while 89.5% of patients achieved 50% reduction in supplemental oxygen compared to 66.7% for placebo. Moreover, 73.7% of patients were discharged by day 14 in the opaganib-arm compared to 55.6% for placebo. Median total oxygen requirement over 14 days was reduced by 68% in the opaganib-arm versus 46.7% for placebo.
Meanwhile, RedHill is set to start a phase II/III study on its second coronavirus candidate, RHB-107 for addressing patients with symptomatic COVID-19 who do not require hospitalization. The FDA cleared an investigational new drug application for the study in November.
Redhill Biopharma Ltd. Price
Redhill Biopharma Ltd. price | Redhill Biopharma Ltd. Quote
Zacks Rank & Stocks to Consider
RedHill currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the healthcare sector include BioLineRx , United Therapeutics (UTHR - Free Report) and Sierra Oncology , all carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BioLineRx’s loss per share estimates have narrowed from $1.36 to 84 cents for 2021 over the past 30 days. Shares of the company have increased 41.4% in the past six months.
United Therapeutics’ earnings per share estimates have increased from $11.49 to $11.59 for 2021 over the past 30 days. Over the trailing six months period, shares of the company have rallied 38.6%.
Sierra Oncology’s loss per share estimates have narrowed from $5.89 to $5.65 for 2021 over the past 60 days. In the past six months, shares of the company have gained 36.6%.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>